Background Information

Claudin-18 (CLDN18) is a member of a large family of four-span transmembrane proteins called Claudins. These proteins are the essential components of the mammalian tight junctions (TJs) in epithelial cells. Claudin-18 has two splice variants, 18.1 and 18.2. While CLDN18.1 is specifically expressed in the lung tissue, CLDN18.2 expression in normal tissue is more restricted and is only detected in small patches of stomach mucosal. CLDN18.2 expression is elevated in many types of epithelial cancers including stomach, esophagus, pancreatic and ovarian cancers. The expression of CLDN18.2 is not only detected in primary tumors, but also in the metastatic sites. Therefore, CLDN18.2 is an ideal target for monoclonal antibody-based cancer therapies.

KATO III is a human gastric carcinoma cell line which expresses lower levels of human CLDN18.2. We stably transfected full length human CLDN18.2 into KATO III cells and generated stable cell pools which express more than 100 fold higher expression of human CLDN18.2 comparing to the parental cells

Product Specifications

Representative Data

Detection of human CLDN18.2 expression on human CLDN18.2-KATO III cells (Cat. #C3016) using recombinant anti-huCLDN18.2 mAbs D10C (Cat. #A1008) and E9 (Cat. #A1013), followed by staining with a secondary PE-anti-human IgG antibody

References

---

Türeci O. et al. (2011) “Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals”. Gene, 481(2), p83-92.

Sahin U. et al. (2008) “Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development”. Clin. Cancer Res. 14 (23) p7624-7634.

Niimi T. et al. (2001) “Claudin-18, a Novel Downstream Target Gene for the T/EBP/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Speci?c Isoforms through Alternative Splicing”. Mol. Cell. Biol. 21(21), p7380-7390.